ArticleTheranostics2012
Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging.
Article in Theranostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 188 citations in OpenAlex.
- Conjugation of Functionalized Gold Nanorods and Copper (I)-Based Drug: An Anisotropic Nano Drug Delivery System.Nanomaterials (Basel, Switzerland) · 2026Article
- Three-dimensional bio-derived materials for biomedical applications: challenges and opportunities.RSC advances · 2025Review
- Gold nanorod-based smart platform for efficient cellular uptake and combination therapy.RSC advances · 2024Article
- Article
- Advanced Optical Imaging-Guided Nanotheranostics towards Personalized Cancer Drug Delivery.Nanomaterials (Basel, Switzerland) · 2022Review
- The Emerging Role of Ultrasonic Nanotechnology for Diagnosing and Treatment of Diseases.Frontiers in medicine · 2022Review
- Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.Current drug metabolism · 2022Review
- Computational study of therapeutic potential of phosphorene as a nano-carrier for drug delivery of nebivolol for the prohibition of cardiovascular diseases: a DFT study.Journal of molecular modeling · 2021Article
- The Synthesis and Evaluation of RGD-Conjugated Chitosan Gel as Daily Supplement for Body Weight Control.Materials (Basel, Switzerland) · 2021Article
- Multifunctional Gold Nanorod for Therapeutic Applications and Pharmaceutical Delivery Considering Cellular Metabolic Responses, Oxidative Stress and Cellular Longevity.Nanomaterials (Basel, Switzerland) · 2021Review
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Doxorubicin (DOX) Gadolinium-Gold-Complex: A New Way to Tune Hybrid Nanorods as Theranostic Agent.International journal of nanomedicine · 2021Article
- Novel Chemo-Photothermal Therapy in Breast Cancer Using Methotrexate-Loaded Folic Acid Conjugated Au@SiONanoscale research letters · 2020Article
- Improving nanotherapy delivery and action through image-guided systems pharmacology.Theranostics · 2020Review
- A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics.Theranostics · 2020Article
- Poly-amino acids coated gold nanorod and doxorubicin for synergistic photodynamic therapy and chemotherapy in ovarian cancer cells.Bioscience reports · 2019Article
- Article
- Bubble-Manipulated Local Drug Release from a Smart Thermosensitive Cerasome for Dual-Mode Imaging Guided Tumor Chemo-Photothermal Therapy.Theranostics · 2019Article
- Gold nanorod-encapsulated biodegradable polymeric matrix for combined photothermal and chemo-cancer therapy.International journal of nanomedicine · 2019Article
- Gold Nanorod-Based Nanohybrids for Combinatorial Therapeutics.ACS omega · 2018Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
A multifunctional gold nanorod (GNR)-based nanoplatform for targeted anticancer drug delivery and positron emission tomography (PET) imaging of tumors was developed and characterized. An anti-cancer drug (i.e., doxorubicin (DOX)) was covalently conjugated onto PEGylated (PEG: polyethylene glycol) GNR nanocarriers via a hydrazone bond to achieve pH-sensitive controlled drug release. Tumor-targeting ligands (i.e., the cyclo(Arg-Gly-Asp-D-Phe-Cys) peptides, cRGD) and (64)Cu-chelators (i.e., 1,4,7-triazacyclononane-N, N', N''-triacetic acid (NOTA)) were conjugated onto the distal ends of the PEG arms to achieve active tumor-targeting and PET imaging, respectively. Based on flow cytometry analysis, cRGD-conjugated nanocarriers (i.e., GNR-DOX-cRGD) exhibited a higher cellular uptake and cytotoxicity than non-targeted ones (i.e., GNR-DOX) in vitro. However, GNR-DOX-cRGD and GNR-DOX nanocarriers had similar in vivo biodistribution according to in vivo PET imaging and biodistribution studies. Due to the unique optical properties of GNRs, this multifunctional GNR-based nanoplatform can potentially be optimized for combined cancer therapies (chemotherapy and photothermal therapy) and multimodality imaging (PET, optical, X-ray computed tomography (CT), etc.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.